Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at greater risk.
Lin Xie, MS, MA
Advertisement
Articles by Lin Xie, MS, MA
Advertisement
Latest Updated Articles
Journey to Anticoagulant Access Following Payer Rejection of ApixabanPublished: November 7th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color
4
Mortality Gap Between Puerto Rico and the US Mainland Among Medicare Advantage Enrollees
5
